XML 142 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Impairment charges / (reversals)
 12 Months Ended
Dec. 31, 2021
Text block [abstract]  
Impairment charges / (reversals)
15 Impairment charges / (reversals)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
Impairment charges / (reversals) comprise:
   
                2021
                     2020                     2019  
       
Impairment charges on financial assets, excluding receivables
      52       291       133  
       
Impairment reversals on financial assets, excluding receivables
      (98 )      (29 )      (73 ) 
       
Impairment charges and reversals on non-financial assets and receivables
      60       128       109  
       
Total
   
 
15
 
  
 
391
 
  
 
169
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
Impairment charges on financial assets, excluding receivables, from:
   
                2021
                     2020                     2019  
       
Shares
      3        42        7   
       
Debt securities and money market instruments
      9       162       50  
       
Loans
      40       87       76  
       
Total
   
 
52
 
  
 
291
 
  
 
133
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
Impairment reversals on financial assets, excluding receivables, from:
   
                2021
                     2020                     2019  
       
Shares
      (8 )      -       -  
       
Debt securities and money market instruments
      (30 )      (26 )      (67 ) 
       
Loans
      (55 )      (2 )      (5 ) 
Other
      (4 )      (1 )      (1 ) 
       
Total
   
 
(98
) 
  
 
(29
) 
  
 
(73
) 
 
Impairment charges on financial assets in 2020 were mainly driven by Americas impairments on public fixed income holdings, primarily in the energy sector, as a consequence of the weakening demand related to the nationwide lockdown due to COVID-19.
Impairment charges on non-financial assets and receivables in 2020 amount to EUR 128 million and are mainly related to a valuation allowance due to the ongoing rehabilitation process of a reinsurer of Aegon Americas for EUR 68 million and the impairment of an associate company of Aegon the Netherlands for EUR 17 million.
Impairment charges/(reversals) on non-financial assets and receivables in 2019 amounted to EUR 109 million and were mainly related to a write-off of VOBA and DPAC amounting to EUR 76 million as a result of a liability adequacy test (LAT) deficit in Aegon the Netherlands. Refer to note 34 “Insurance contracts” for further details on the LAT impact. In addition, 2019 included the dilution of the capital injections in India (ALIC) of EUR 10 million and impairments to software in the Netherlands of EUR 9 million.
For more details on impairments on financial assets, excluding receivables, refer to note 4 Financial risks.